Approach to Probable Malignant Renal Mass with Liver Metastases

Initial Diagnostic Workup

The National Comprehensive Cancer Network recommends initiating systemic therapy as the first-line treatment for patients with probable malignant renal mass and liver metastases, particularly if the patient has intermediate- or poor-risk features, high metastatic burden, or requires immediate systemic treatment 1, 2, 3
High-quality multiphase cross-sectional imaging (CT or MRI) of the abdomen should be obtained to characterize the renal mass, assess for venous involvement, and evaluate liver metastases, as recommended by the Journal of Urology and Annals of Oncology 4, 5
Chest CT should be performed to evaluate for thoracic metastases, according to the Journal of Urology 4, 6
Tissue diagnosis via renal mass biopsy should be obtained to confirm malignancy and determine histologic subtype, as recommended by the Annals of Oncology and the National Comprehensive Cancer Network 1, 5, 7
Laboratory evaluation must include complete metabolic panel, complete blood count, urinalysis, lactate dehydrogenase (LDH), corrected calcium, hemoglobin, neutrophil and platelet counts for IMDC risk stratification, as recommended by the Journal of Urology and the National Comprehensive Cancer Network 1, 2, 4, 6

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model uses 6 factors to categorize patients, including Karnofsky performance status <80%, time from diagnosis to treatment <1 year, hemoglobin below lower limit of normal, corrected calcium above upper limit of normal, neutrophil count above upper limit of normal, and platelet count above upper limit of normal, as recommended by the National Comprehensive Cancer Network 1, 2
Patients with favorable risk (0 factors) may consider cytoreductive nephrectomy followed by systemic therapy if low-volume metastases and excellent performance status, as recommended by the National Comprehensive Cancer Network and Annals of Oncology 1, 3
Patients with intermediate risk (1-2 factors) should prefer systemic therapy, while cytoreductive nephrectomy may be considered only if single IMDC risk factor and low metastatic burden, as recommended by the National Comprehensive Cancer Network and Annals of Oncology 2, 3
Patients with poor risk (≥3 factors) should receive systemic therapy as initial treatment, as recommended by the National Comprehensive Cancer Network and Annals of Oncology 1, 3

For patients with high metastatic burden or intermediate/poor-risk features, initiate systemic therapy without upfront nephrectomy, as recommended by the National Comprehensive Cancer Network, Annals of Oncology, and Journal for ImmunoTherapy of Cancer 1, 2, 3, 9
For patients with low-volume metastases and favorable risk, consider cytoreductive nephrectomy followed by systemic therapy, as recommended by the National Comprehensive Cancer Network, Annals of Oncology, and Journal for ImmunoTherapy of Cancer 1, 2, 3, 9
For patients with oligometastatic disease, consider multidisciplinary evaluation for combined surgical approach, including nephrectomy plus hepatic metastasectomy, as recommended by the National Comprehensive Cancer Network, Annals of Oncology, and Journal for ImmunoTherapy of Cancer 2, 3, 9
For patients with symptomatic primary tumor, perform palliative nephrectomy regardless of metastatic burden, as recommended by the National Comprehensive Cancer Network and Annals of Oncology 2, 3

First-line systemic therapy options for clear cell histology include immune checkpoint inhibitor combinations or TKI plus immunotherapy combinations, as recommended by the Annals of Oncology and the National Comprehensive Cancer Network 2, 5
Alternative regimens include sunitinib, pazopanib, or other VEGF-targeted agents, as recommended by the Annals of Oncology and the National Comprehensive Cancer Network 2, 3, 5

When systemic therapy achieves disease control, consider local consolidation, including hepatic resection, SBRT, or ablative techniques, as recommended by the Annals of Oncology, Journal for ImmunoTherapy of Cancer, and the National Comprehensive Cancer Network 2, 3, 5, 9

Do not perform upfront cytoreductive nephrectomy in intermediate/poor-risk patients with high metastatic burden requiring immediate systemic therapy, as recommended by the National Comprehensive Cancer Network, Annals of Oncology, and Journal for ImmunoTherapy of Cancer 1, 2, 3
Do not skip tissue diagnosis, as histologic subtype fundamentally alters systemic therapy selection, as recommended by the Annals of Oncology, the National Comprehensive Cancer Network, and Praxis Medical Insights 1, 5, 7
Do not use MSKCC criteria alone, as IMDC criteria are more relevant to contemporary targeted and immunotherapy era, as recommended by the National Comprehensive Cancer Network 1, 2